Milvexian

DB16233InvestigationalSmall molecule

Milvexian is under investigation in clinical trial NCT03766581 (A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel).

Mechanism: Pharmacologically active on Coagulation factor XI
Curator reviewed
Formula / weight: C₂₈H₂₃Cl₂F₂N₉O₂ · 626.45 g/mol (avg)
Code names: BMS-986177 · JNJ-70033093

Resolves to

Compound

UNII0W79NDQ608CAS1802425-99-5ChEMBLCHEMBL4112929

Structure

InChIKeyFSWFYCYPTDLKON-CMJOXMDJSA-NSMILESC[C@@H]1CCC[C@H](N2C=NC(=CC2=O)C2=CC(Cl)=CC=C2N2C=C(Cl)N=N2)C2=CC(=CC=N2)C2=C(NC1=O)C=NN2C(F)F

Targets

P03951F11

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

16Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Milvexian, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account